EVALUATION OF NOVEL RISK SCORE FOR REFINING STROKE RISK IN “LOW-RISK” ATRIAL FIBRILLATION PATIENTS WITH CHA2DS2-VASC SCORE OF 0 AND 1 Academic Article uri icon

abstract

  • Background Patients with atrial fibrillation benefit from initiating anticoagulation therapy when the annual risk of stroke is 1% or above. Anticoagulation is considered non-beneficial in patients with a CHA 2 DS 2-VASc of 0, and is of uncertain benefit in patients with a score of 1. We followed patients with CHA 2 DS 2-VASc score of 0 and 1 to identify patients among them who may benefit from anticoagulation Methods Using a prospective historical cohort, we analyzed data of all incident non-valvular AF cases between 2004 and 2015 with a CHA 2 DS 2-VASc score of 0 or 1. Primary endpoint was first incidence of ischemic stroke. The Clalit Risk Score was computed using multiple logistic regression models on the incidence of stroke, and further converted into a point score. Results We identified 11,860 patients, average age 51.5±12.5 years, 73.7% male. Mean follow-up time was 3.9 years. In the …

publication date

  • January 1, 2018